These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 17336267)
1. Dynamic interplay between the neutral glycosphingolipid CD77/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells. Jarvis RM; Chamba A; Holder MJ; Challa A; Smith DC; Hodgkin MN; Lord JM; Gordon J Biochem Biophys Res Commun; 2007 Apr; 355(4):944-9. PubMed ID: 17336267 [TBL] [Abstract][Full Text] [Related]
2. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Mangeney M; Lingwood CA; Taga S; Caillou B; Tursz T; Wiels J Cancer Res; 1993 Nov; 53(21):5314-9. PubMed ID: 8221667 [TBL] [Abstract][Full Text] [Related]
3. CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin. Gordon J; Challa A; Levens JM; Gregory CD; Williams JM; Armitage RJ; Cook JP; Roberts LM; Lord JM Cell Death Differ; 2000 Sep; 7(9):785-94. PubMed ID: 11042673 [TBL] [Abstract][Full Text] [Related]
4. Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces. Holder MJ; Chamba A; Hardie DL; Deans JP; Gordon J Leuk Res; 2004 Nov; 28(11):1197-202. PubMed ID: 15380345 [TBL] [Abstract][Full Text] [Related]
5. Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and verotoxin-1. Tétaud C; Falguières T; Carlier K; Lécluse Y; Garibal J; Coulaud D; Busson P; Steffensen R; Clausen H; Johannes L; Wiels J J Biol Chem; 2003 Nov; 278(46):45200-8. PubMed ID: 12944404 [TBL] [Abstract][Full Text] [Related]
6. MHC class II proteins contain a potential binding site for the verotoxin receptor glycolipid CD77. George T; Boyd B; Price M; Lingwood C; Maloney M Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1179-85. PubMed ID: 11838965 [TBL] [Abstract][Full Text] [Related]
7. Comparison of adhesion mechanisms and surface protein expression in CD77-positive and CD77-negative Burkitt's lymphoma cells. Jackson T; Van Exel C; Reagans K; Verret R; Maloney M Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1195-200. PubMed ID: 11838967 [TBL] [Abstract][Full Text] [Related]
9. CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. Khine AA; Firtel M; Lingwood CA J Cell Physiol; 1998 Aug; 176(2):281-92. PubMed ID: 9648915 [TBL] [Abstract][Full Text] [Related]
10. Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating lyn kinase activity in human B cells. Mori T; Kiyokawa N; Katagiri YU; Taguchi T; Suzuki T; Sekino T; Sato N; Ohmi K; Nakajima H; Takeda T; Fujimoto J Exp Hematol; 2000 Nov; 28(11):1260-8. PubMed ID: 11063874 [TBL] [Abstract][Full Text] [Related]
11. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. Rapoport AP; Simons-Evelyn M; Chen T; Sidell R; Luhowskyj S; Rosell K; Obrig T; Hicks D; Hinkle PM; Nahm M; Insel RA; Abboud CN Blood Cells Mol Dis; 2001; 27(3):610-24. PubMed ID: 11482875 [TBL] [Abstract][Full Text] [Related]
12. CD77: an antigen of germinal center B cells entering apoptosis. Mangeney M; Richard Y; Coulaud D; Tursz T; Wiels J Eur J Immunol; 1991 May; 21(5):1131-40. PubMed ID: 1709864 [TBL] [Abstract][Full Text] [Related]
13. CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. Maloney MD; Lingwood CA J Exp Med; 1994 Jul; 180(1):191-201. PubMed ID: 7516406 [TBL] [Abstract][Full Text] [Related]
14. Expression of differentiation and adhesion molecules in sporadic Burkitt's lymphoma. Aiello A; Delia D; Fontanella E; Giardini R; Rilke F; Della Porta G Hematol Oncol; 1990; 8(4):229-38. PubMed ID: 2210691 [TBL] [Abstract][Full Text] [Related]
15. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427 [TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Semac I; Palomba C; Kulangara K; Klages N; van Echten-Deckert G; Borisch B; Hoessli DC Cancer Res; 2003 Jan; 63(2):534-40. PubMed ID: 12543813 [TBL] [Abstract][Full Text] [Related]
18. CD20-induced B cell death can bypass mitochondria and caspase activation. van der Kolk LE; Evers LM; Omene C; Lens SM; Lederman S; van Lier RA; van Oers MH; Eldering E Leukemia; 2002 Sep; 16(9):1735-44. PubMed ID: 12200688 [TBL] [Abstract][Full Text] [Related]
19. A comparison of Verotoxin B-subunit (Stx1B) and CD77 antibody to define germinal centre populations. Bailey S; Mardell C; Wheatland L; Zola H; Macardle PJ Cell Immunol; 2005; 236(1-2):167-70. PubMed ID: 16165112 [TBL] [Abstract][Full Text] [Related]
20. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Unruh TL; Li H; Mutch CM; Shariat N; Grigoriou L; Sanyal R; Brown CB; Deans JP Immunology; 2005 Oct; 116(2):223-32. PubMed ID: 16162271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]